Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial.

CONCLUSION: In patients with SCAD, the addition of QXJYG to standard therapy was associated with reduced risk of nonfatal MI and the composite 'hard' endpoint of cardiovascular death, nonfatal MI and stroke. (http://www.chictr.org.cn/showproj.aspx?proj=5200, ChiCTR-TRC-13004370). PMID: 31780034 [PubMed - in process]
Source: Complementary Therapies in Medicine - Category: Complementary Medicine Authors: Tags: Complement Ther Med Source Type: research

Related Links:

AbstractPurpose of the ReviewThis review highlights selected cardiovascular disease (CVD) prevention studies presented at the 2019 American Heart Association (AHA) Scientific Sessions.Recent FindingsSeveral important cardiovascular prevention studies were presented at the 2019 AHA Scientific Sessions. Results from the Colchicine Cardiovascular Outcomes Trial (COLCOT) showed that low-dose colchicine reduces the risk of recurrent CVD events among patients with recent myocardial infarction. A prospective analysis from the UK Biobank cohort demonstrated that the increased CVD risk associated with clonal hematopoiesis of indete...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
AbstractBackgroundImpaired renal function (IRF) is associated with increased risks of both ischemic and bleeding events. Ticagrelor has been shown to provide greater absolute reduction in ischemic risk following acute coronary syndrome (ACS) in those with versus without IRF.MethodsA pre-specified sub-analysis of the randomized GLOBAL LEADERS trial (n = 15,991) comparing the experimental strategy of 23-month ticagrelor monotherapy (after 1-month ticagrelor and aspirin dual anti-platelet therapy [DAPT]) with 12-month DAPT followed by 12-month aspirin after percutaneous coronary intervention (PCI) in ACS and sta...
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
Publication date: Available online 7 January 2020Source: The Lancet Diabetes &EndocrinologyAuthor(s): Hertzel C Gerstein, Robert Hart, Helen M Colhoun, Rafael Diaz, Mark Lakshmanan, Fady T Botros, Jeffrey Probstfield, Matthew C Riddle, Lars Rydén, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Alvaro Avezum, Jan Basile, Ignacio Conget, William C Cushman, Nicolae Hancu, Markolf Hanefeld, Petr Jansky, Matyas KeltaiSummaryBackgroundCardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the ...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
Publication date: January 2020Source: Archives of Cardiovascular Diseases Supplements, Volume 12, Issue 1Author(s): C. Bernard, M.C. Morgant, A. Jazayeri, A. Bernard, O. BouchotDuring acute phase of myocardial infarction (MI), the culprite artery must be revascularized quickly with angioplasty. Then, surgery complete the procedure in a second time. If surgery is emergent, resulting death rate is really high; 15 to 20% of patients operated on within the first 48 hours and 4 to 5% for patients operated on after. Various factors influence mortality rate; timing of surgical revascularization and patient's preoperative sta...
Source: Archives of Cardiovascular Diseases Supplements - Category: Cardiology Source Type: research
ConclusionAmong patients with AF, OSA is an independent risk factor for MACNE and, more specifically, stroke/SE.Graphical Abstract
Source: American Heart Journal - Category: Cardiology Source Type: research
Low-dose aspirin reduces the frequency of adverse vascular events in those at increased risk of occlusive cardiovascular disease (CVD). People who benefit include those: with a history of myocardial infarction, ischaemic stroke, unstable or stable angina, peripheral arterial disease, or atrial fibrillation (1). The pathophysiology of CVD risk contributes to cognitive decline through multiple pathways that include cerebral hypo-perfusion, hypoxia, hippocampal atrophy, emboli, or infarcts (2,3). However, the value of aspirin use in prevention of cognitive impairment remains uncertain since results relating to the influence o...
Source: Maturitas - Category: Primary Care Authors: Source Type: research
AbstractBackgroundData about the clinical outcomes of ACS patients with advanced renal dysfunction (estimated glomerular filtration rate  
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
CONCLUSIONS: In patients with appropriate indications according to Chinese AUC, coronary revascularization was associated with significantly lower risk of MACCEs at 1 year. No benefit was found in coronary revascularization in patients with inappropriate indications. Our findings provide evidence for using Chinese AUC to guide clinical decision-making. CLINICAL TRIAL REGISTRATION: NCT02880605. https://www.clinicaltrials.gov. PMID: 31923098 [PubMed - in process]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
Publication date: January 2020Source: Canadian Journal of Cardiology, Volume 36, Issue 1Author(s): Mohammed Shurrab, Asaf Danon, Sami Alnasser, Benedict Glover, Anna Kaoutskaia, Mark Henderson, David Newman, Eugene Crystal, Dennis KoAbstractBackgroundThe choice of antithrombotic therapy for atrial fibrillation (AF) patients who have an acute coronary syndrome (ACS) or have undergone percutaneous coronary intervention (PCI) is challenging. We aimed to assess outcomes between dual-antithrombotic therapy with the use of direct-acting oral anticoagulants (DOACs) plus an antiplatelet agent (dual therapy) compared with warfarin ...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
ConclusionIn the present study, no association was found between aspirin use in TTS patients and a reduced risk of MACCE at 30 ‐day and 5‐year follow‐up. These findings should be confirmed in adequately powered randomized controlled trials.ClinicalTrials.gov Identifier: NCT01947621.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
More News: Alternative and Complementary Therapies | Cardiology | Cardiovascular | China Health | Complementary Medicine | Heart | Heart Attack | Ischemic Stroke | Stroke